Cargando…

Simultaneous Visualization of (161)Tb- and (177)Lu-Labeled Somatostatin Analogues Using Dual-Isotope SPECT Imaging

The decay of terbium-161 results in the emission of β¯-particles as well as conversion and Auger electrons, which makes terbium-161 interesting for therapeutic purposes. The aim of this study was to use dual-isotope SPECT imaging in order to demonstrate visually that terbium-161 and lutetium-177 are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borgna, Francesca, Barritt, Patrick, Grundler, Pascal V., Talip, Zeynep, Cohrs, Susan, Zeevaart, Jan Rijn, Köster, Ulli, Schibli, Roger, van der Meulen, Nicholas P., Müller, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070648/ https://www.ncbi.nlm.nih.gov/pubmed/33921467 http://dx.doi.org/10.3390/pharmaceutics13040536

Ejemplares similares

Production and characterization of no-carrier-added (161)Tb as an alternative to the clinically-applied (177)Lu for radionuclide therapy
por: Gracheva, Nadezda, et al.
Publicado: (2019)

Combination of terbium-161 with somatostatin receptor antagonists—a potential paradigm shift for the treatment of neuroendocrine neoplasms
por: Borgna, Francesca, et al.
Publicado: (2021)

(161)Tb-DOTATOC Production Using a Fully Automated Disposable Cassette System: A First Step Toward the Introduction of (161)Tb into the Clinic
por: Favaretto, Chiara, et al.
Publicado: (2023)

Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate
por: Haller, Stephanie, et al.
Publicado: (2016)

A Step-by-Step Guide for the Novel Radiometal Production for Medical Applications: Case Studies with (68)Ga, (44)Sc, (177)Lu and (161)Tb
por: Talip, Zeynep, et al.
Publicado: (2020)

Establishment of a clinical SPECT/CT protocol for imaging of (161)Tb
por: Marin, I., et al.
Publicado: (2020)

Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
por: Müller, Cristina, et al.
Publicado: (2019)

Therapeutic Potential of (47)Sc in Comparison to (177)Lu and (90)Y: Preclinical Investigations
por: Siwowska, Klaudia, et al.
Publicado: (2019)

Radiation doses from (161)Tb and (177)Lu in single tumour cells and micrometastases
por: Alcocer-Ávila, Mario E., et al.
Publicado: (2020)

Precise activity measurements of medical radionuclides using an ionization chamber: a case study with Terbium-161
por: Juget, Frédéric, et al.
Publicado: (2022)

Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection
por: Verburg, Frederik A., et al.
Publicado: (2023)

Dosimetric Analysis of the Short-Ranged Particle Emitter (161)Tb for Radionuclide Therapy of Metastatic Prostate Cancer
por: Bernhardt, Peter, et al.
Publicado: (2021)

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [(177)Lu]Lu-OPS201 Compared to the Agonist [(177)Lu]Lu-DOTA-TATE
por: Mansi, Rosalba, et al.
Publicado: (2021)

Promising potential of [(177)Lu]Lu-DOTA-folate to enhance tumor response to immunotherapy—a preclinical study using a syngeneic breast cancer model
por: Guzik, Patrycja, et al.
Publicado: (2020)

Terbium-149 for targeted alpha therapy
por: Borgna, Francesca, et al.
Publicado: (2021)

Quantitative accuracy of (177)Lu SPECT imaging for molecular radiotherapy
por: Mezzenga, Emilio, et al.
Publicado: (2017)

Cyclotron production and radiochemical purification of terbium-155 for SPECT imaging
por: Favaretto, C., et al.
Publicado: (2021)

Preclinical investigations using [(177)Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer
por: Tschan, Viviane J., et al.
Publicado: (2022)

Quantitative (177)Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system
por: Beauregard, Jean-Mathieu, et al.
Publicado: (2011)

Accuracy of (177)Lu activity quantification in SPECT imaging: a phantom study
por: Uribe, Carlos F., et al.
Publicado: (2017)

Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)
por: Hosono, Makoto, et al.
Publicado: (2018)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

Comprehensive SPECT/CT system characterization and calibration for (177)Lu quantitative SPECT (QSPECT) with dead-time correction
por: Frezza, Andrea, et al.
Publicado: (2020)

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [(177)Lu]Lu-Satoreotide Tetraxetan and the Agonist [(177)Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST(2)-Positive Tumours
por: Plas, Pascale, et al.
Publicado: (2022)

Somatostatin receptor saturation after administration of high peptide amounts of [(177)Lu]Lu-HA-DOTATATE: when enough is enough
por: Siebinga, Hinke, et al.
Publicado: (2022)

Evaluation of a New (177)Lu-Labeled Somatostatin Analog for the Treatment of Tumors Expressing Somatostatin Receptor Subtypes 2 and 5
por: Mansi, Rosalba, et al.
Publicado: (2020)

Therapeutic Response of CCKBR-Positive Tumors to Combinatory Treatment with Everolimus and the Radiolabeled Minigastrin Analogue [(177)Lu]Lu-PP-F11N
por: Grzmil, Michal, et al.
Publicado: (2021)

(177)Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model
por: Beykan, Seval, et al.
Publicado: (2016)

EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
por: Sjögreen Gleisner, Katarina, et al.
Publicado: (2022)

Improving quantitative dosimetry in (177)Lu-DOTATATE SPECT by energy window-based scatter corrections
por: de Nijs, Robin, et al.
Publicado: (2014)

In vivo quantification of (177)Lu with planar whole-body and SPECT/CT gamma camera imaging
por: Bailey, Dale L., et al.
Publicado: (2015)

Impact of dead time on quantitative (177)Lu-SPECT (QSPECT) and kidney dosimetry during PRRT
por: Desy, Alessandro, et al.
Publicado: (2020)

Reconstructed SPECT images of (177)Lu homogeneous cylindrical phantom used for calibration and texture analysis
por: Mezzenga, Emilio, et al.
Publicado: (2022)

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: de Keizer, Bart, et al.
Publicado: (2008)

A phase I/II study of the safety and efficacy of [(177)Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours
por: Wild, Damian, et al.
Publicado: (2023)

Quantitative accuracy of (177)Lu SPECT reconstruction using different compensation methods: phantom and patient studies
por: Hippeläinen, Eero, et al.
Publicado: (2016)

SPECT image segmentation for estimation of tumour volume and activity concentration in (177)Lu-DOTATATE radionuclide therapy
por: Gustafsson, Johan, et al.
Publicado: (2017)

Towards accurate (177)Lu SPECT activity quantification and standardization using lesion-to-background voxel ratio
por: Raskin, Stanislav, et al.
Publicado: (2023)

Lu-177-PSMA dosimetry for kidneys and tumors based on SPECT images at two imaging time points
por: Chen, Gefei, et al.
Publicado: (2023)

Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin (177)Lu-PP-F11N
por: Grob, Nathalie M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jjq96847pdld2vup3auojjbl59